Emulsion drops are most effective for improving tear stability

Article

Administering emulsion drops in dry eye patients improves tear stability and decreases osmolarity and corneal staining.

Administering emulsion drops in dry eye patients improves tear stability and decreases osmolarity and corneal staining, revealed a study in Cornea.

The investigation, led by Dr Louise McCann, Department of Vision Sciences, Glasgow Caledonian University, UK, included 75 dry eye patients who were randomized into 3 groups. Each subject received either sodium hyaluronate, hydroxypropyl methylcellulose (HPMC) or emulsion drops four times daily for 90 days. At days 7 and 60 a compliance visit was conducted.

In all groups a significant improvement in evaporation and all symptoms was recorded. However, there were no significant findings in tear turnover rate (TTR) for any of the three solutions.

In the emulsion and sodium hyaluronate group there was a significant difference in tear stability and non-invasive tear break-up time. The emulsion group demonstrated a significant decrease in osmolarity and corneal staining.

All therapy groups presented with a significant reduction in evaporation, although there was no significant changes in TTR demonstrated in any of the groups. The results suggest that long-term use of emulsion drops demonstrates consistency with lipid layer tear film improvements.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.